NSE List Price : ₹395.20

subscription

Category	Times
QIBs	196.77x
HNIs	597.63x
Retail	401.36x
Total : 385.40x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	2	1,200	₹249,600
Retail Maximum	2	1,200	₹249,600
S-HNI Minimum	3	1,800	₹374,400
S-HNI Maximum	8	4,800	₹998,400
B-HNI Minimum	9	5,400	₹1,123,200

About the Company

Avience Biomedicals Limited, incorporated in June 2024, is engaged in the manufacturing, supply, and export of molecular diagnostic products, laboratory equipment, and testing solutions. The company operates in the fields of molecular biotechnology, genomics, and in vitro diagnostics (IVD).

The company has expanded its portfolio from IVD rapid testing kits to a broader range of healthcare and diagnostic products, including biochemistry, hematology, and serology-related medical devices. Its product offerings comprise Rapid Test Kits, Molecular Diagnostic Solutions, Biochemistry Analyzers and Reagents, Hematology Analyzers, and various Medical Devices.

Avience Biomedicals serves a diverse customer base that includes pathology laboratories, microbiology laboratories, hospitals, and research institutions across India as well as international markets. In addition to its manufacturing activities, the company is involved in the trading and distribution of medical equipment. Its manufacturing unit is situated in Noida, Uttar Pradesh.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2024	₹24.37	₹21.43	₹2.14	₹34.65
2025	₹45.97	₹36.17	₹7.23	₹56.52
Jan 2026	₹41.94	₹34.06	₹5.74	₹66.07

Company Promoter

Mr. Dharam Deo Choudhary

Mr. Ram Nagina Choudhary

Mr. Janardan Pal

Ms. Deepa Choudhary

Know before investing

• • Strengths

  Diverse and Advanced Product Range: Provides an extensive portfolio of IVD rapid test kits, diagnostic solutions, medical devices, and advanced biochemistry and hematology analyzers, supported by its collaboration with Mindray.

  Robust Quality and Regulatory Standards: Maintains high levels of quality and compliance through adherence to recognized certifications and standards, including ISO 13485, ISO 9001, CE Marking, and GMP, ensuring product safety, consistency, and regulatory conformity.

• • Risks

  Regulatory Risk: The healthcare and pharmaceutical sectors operate under strict regulatory frameworks. Non-compliance with applicable domestic or international regulations may result in penalties, increased compliance expenses, or interruptions to business operations.

  Supply Chain Risk: The company depends on external vendors for the procurement of medical devices, equipment, raw materials, and components. Any disruption in supply, delays in procurement, or escalation in input costs could negatively impact operational efficiency and financial performance.

Objects of the Issue & Utilisation of proceeds

Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh.

Funding the working capital requirements of the Company.

General Corporate Purpose.

Company  Address

Avience Biomedicals Ltd.
C-11, Block-C
Community Centre,
Janakpuri A-3,
Delhi, New Delhi, 110058
Phone: 1800-12-04-636
Email: info@avienbio.com
Website: https://avienbio.com/

IPO Registrar

Skyline Financial Services Pvt. Ltd.
Phone: 02228511022
Email: ipo@skylinerta.com
Website: https://www.skylinerta.com/ipo.php

IPO Review

May Apply